Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
Abbott has previously opposed legislation to test strips, but noted an 89% increase in fentanyl deaths in Texas over the past year.
Read Full NewsMerck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.
New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.
New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.
5 FDA Headlines You Missed in November 2025
1.
Recently released national data on drug use and abuse among Americans.
2.
Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients
3.
Base-edited T-cell therapy offers additional hope for treating resistant leukemia.
4.
Scholastic performance is a key concern for young cancer patients, study finds
5.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
1.
Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer
2.
Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology
3.
Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances
4.
A Review of Cancer Treatment Evolution Towards Stem Cells and Gene Therapy
5.
Clinical Analysis of Prostate Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge